Studies
Current Endometriosis Research
Understanding endometriosis requires access to reliable, up-to-date research. This Study Page is for those who want to explore the evidence behind current knowledge. It is a curated, searchable research index for endometriosis-specific publications and ongoing clinical studies, and invites you to visually explore the interrelations between research topics that may not be obvious at first glance.
Do you want to:
Studies you can join
Clinical studies seeking participants
Currently recruiting
ENDOVA: Vagus Nerve Stimulation in Symptomatic Endometriosis
MedUni Vienna is recruiting for ENDOVA, a prospective, double-blind, sham-controlled, randomized pilot study evaluating whether gentle auricular vagus nerve stimulation with the VIVO® class IIa medical device can improve quality of life and pain in people with symptomatic endometriosis. Participation lasts approximately 4.5 months and includes 6 weeks of device use, weekly appointments in Vienna during the device phase, and an electronic pain diary throughout the study. Basic criteria include age 18-51, surgically confirmed endometriosis or diagnosis by ultrasound/MRI, menstrual pain or chronic lower abdominal pain, and no current hormonal endometriosis therapy; people with a pacemaker cannot participate.
ELECTRE
A single-center randomized study evaluating the efficacy and tolerability of a transcutaneous electrical nerve stimulation (TENS) device for managing endometriosis-associated pelvic pain. The study compares conventional TENS with microstimulation TENS and is recruiting adult women with endometriosis and/or adenomyosis diagnosed by imaging and/or histology.
microRNA Analysis
A diagnostics study at Cliniques universitaires Saint-Luc investigating epigenetic markers (microRNAs) in participants with and without endometriosis, with the goal of better understanding the disease and supporting future diagnostic approaches. Eligible participants are over 18, have spontaneous menstrual cycles, and are not using contraception. Participation involves providing a menstrual sample and a blood draw; financial compensation may be available.
Recruitment ended - results pending
NOVA – Vipoglanstat (Phase 2)
A randomized, double-blind, placebo-controlled Phase 2 trial by Swedish biotech Gesynta Pharma investigating Vipoglanstat, a non-hormonal and non-opioid compound, for endometriosis-associated pain. Approximately 190 women aged 18–45 are being enrolled across multiple European centers to evaluate efficacy, safety, and optimal dosing.
Endogreet
A potential non-hormonal treatment approach using Tigovit, a green tea extract, in a randomized, double-blind, placebo-controlled study at MedUni Vienna. Green tea extract has shown promise in reducing both pain and inflammation around endometriosis lesions.
IMAGENDO
Imaging study aiming to reduce endometriosis diagnosis time through improved imaging analysis. Participants needed pelvic MRI or transvaginal ultrasound examinations.
ENDOFLEX
A MedUni Vienna study investigating Flexofytol, a curcumin extract preparation, as a potential non-hormonal approach for endometriosis-associated pain. The rationale was based on the inflammatory component of endometriosis symptoms and prior clinical data suggesting anti-inflammatory and antioxidant pain-relief effects of curcumin preparations in osteoarthritis.
Published Endometriosis Research
Browse curated endometriosis publications across various categories. Each entry links back to the original publication source.
1 publication
Largest multi-ancestry GWAS and integrated multi-omics study of endometriosis to date, analyzing ~1.4 million women including 105,869 cases. The study identified 80 genomic risk loci, including 37 new loci, and linked risk signals to pathways involved in cell differentiation, immune and hormonal regulation, tissue remodeling, and inflammation. It also found partial genetic overlap with adenomyosis and interactions between polygenic endometriosis risk and symptoms such as abdominal pain, anxiety, migraine, and nausea; these findings are association-based and do not imply deterministic prediction for individual patients.
Apr 29, 2026